Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Nevena Damjanov, MD

Nevena Damjanov, MD Physician

Section Chief Hematology/Oncology, VA Medical Center Professor of Clinical Medicine Professor AC Professor AC

Dr. Damjanov is employed by Penn Medicine.

Request an Appointment
No Patient Satisfaction Reviews
Why not?

There is no publicly available rating for this medical professional for one of the following reasons:

  1. He or she is not employed by Penn Medicine.
  2. He or she does not see patients.
  3. He or she sees patients but has not yet received the minimum 30 patient satisfaction reviews in the past 12 months, ensuring that the rating is statistically reliable and a true reflection of patient satisfaction.
X

Clinical Specialties

Specialty:

  • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 1996
  • Internal Medicine, 1992
  • Medical Oncology, 1995

Clinical Expertise:

  • Colon Cancer
  • Esophageal Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Drexel University Center City Hahnemann Campus
Residency: Penn State Milton S. Hershey Medical Center
Fellowship: Hospital of the University of Pennsylvania
Fellowship: University Hospitals Case Medical Center

Memberships

American Medical Association, National American Society of Clinical Oncology, National

Hospital Affiliation

Dr. Damjanov is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.

Research

Selected Publications:

Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J.: Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 19 (5): 2018.

Brown JC, Rickels MR, Troxel AB, Zemel BS, Damjanov N, Ky B, Rhim AD, Rustgi AK, Courneya KS, Schmitz KH.: Dose-response effects of exercise on insulin among colon cancer survivors. Endocr Relat Cancer. 25 (1): 2018.

Baumann BC, Wei J, Plastaras JP, Lukens JN, Damjanov N, Hoteit M, Hsu C, Levine M, Mondschein J, Nadolski G, Olthoff K, Reiss KA, Rosen M, Siegelman E, Metz JM, Ben-Josef E.: Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma: High Rates of Local Control With Low Toxicity. Am J Clin Oncol. : 2018.

Shabason JE, Chen J, Apisarnthanarax S, Damjanov N, Giantonio B, Loaiza-Bonilla A, O'Dwyer PJ, O'Hara M, Reiss KA, Teitelbaum U, Wissel P, Drebin JA, Vollmer C, Kochman M, Mick R, Vergara N, Jhala N, Doucette A, Lukens JN, Plastaras JP, Metz JM, Ben-Josef E.: A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer. Cancer Chemother Pharmacol. 81 (3): 2018.

Brown JC, Troxel AB, Ky B, Damjanov N, Zemel BS, Rickels MR, Rhim AD, Rustgi AK, Courneya KS, Schmitz KH.: Dose-response Effects of Aerobic Exercise Among Colon Cancer Survivors: A Randomized Phase II Trial. Clin Colorectal Cancer. 17 (1): 2018.

V. Mazzaferro, B. El-Rayes, C. Cotsoglou, W. P. Harris, N. Damjanov, G. Masi, L. Rimassa, N. Personeni, F. Braiteh, V. Zagonel, K.P. Papadopoulos, T. Hall, Y. Wang, G. Abbadessa, B. Schwart, J. Kazakin, M. Droz Dit Busset, W. Shaib: ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations J Clin Oncol 35 : 2017.

Mark H. O'Hara, Thomas Benjamin Karasic, Irina Vasilevskaya, Maryann Redlinger, Arturo Loaiza-Bonilla, Ursina R. Teitelbaum, Bruce J. Giantonio, Nevena Damjanov, Kim Anna Reiss, Mark Alan Rosen, Daniel F Heitjan, Andrea B. Troxel, Ravi K. Amaravadi, Peter J. O'Dwyer: Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer J Clin Oncol 35 : 2017.

Lorenza Rimassa, Eric Assenat, Markus Peck-Radosavljevic, Vittorina Zagonel, Marc Pracht, Elena Rota-Caremoli, Philippe Mathurin, William Harris, Luigi Bolondi, Maria Reig, Nevena Damjanov, Bruno Daniele, Camillo Porta, Vincenzo Mazzaferro, Giovanni Abbadessa, Brian Schwartz, Maria Lamar, Terri Goldberg, Armando Santoro, Jordi Bruix: Second-Line Tivantinib (ARQ 197) vs Placebo in Patients (Pts) with MET-High Hepatocellular Carcinoma (HCC): Results of the METIV-HCC Phase 3 Trial J Clin Oncol 35 : 2017.

Braxton DR, Saxe D, Damjanov N, Stashek K, Shroff S, Morrissette JD, Tondon R, Furth EE.: Molecular and cytogenomic profiling of hepatic adenocarcinoma expressing inhibinA, a mimicker of neuroendocrine tumors: proposal to reclassify as "cholangioblastic variant of intrahepatic cholangiocarcinoma". Hum Pathol 62 : 232-241,2017.

Jacob E. Shabason, Jerry Chen, Smith Apisarnthanarax, Nevena Damjanov, Bruce Giantonio, Arturo Loaiza-Bonilla, Peter O’Dwyer, Mark O’Hara, Kim Reiss, Ursina Teitelbaum, Paul Wissel, Jeffery Drebin, Charles Vollmer, Michael Kochman, Rosemarie Mick, Norge Vergara, Nirag Jhala, Abigail Berman, Jay Dorsey, Sydney M. Evans, Gary Kao, John. N. Lukens, John P. Plastaras, James M. Metz, Edgar Ben-Josef: A Phase I Dose Escalation Trial of Nab-Paclitaxel and Fixed Dose Radiation in Patients with Unresectable or Borderline Resectable Pancreatic Cancer Association for Clinical and Translational Science Annual Meeting : 2017.

Academic Contact Info

Penn Presbyterian Medical Center
51 North 39th Street
103A MAB

Philadelphia, PA 19104
Phone: (215) 662-8488
Patient appointments: 800-789-7366 (PENN)

Related Links